| Intrinsic Valuation of: STARHEALTH | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2021 | - | - | EPS (FY) | 9 | Market Cap | ₹295B | |||||
| 2022 | - | - (-) | P/E Ratio | 53 | Total Asset | ₹241B | |||||
| 2023 | ₹12B | - (-) | Net Income | ₹6B | Total Debt | ₹5B | |||||
| 2024 | ₹12B | -3.5% (-18.0%) | EBITDA | - | Total Liab | ₹165B | |||||
| 2025 | ₹13B | 9.2% (-2.2%) | Opr Margin | - | Debt/Equity | 0.06 | |||||
| 2026 | ₹18B | 38.5% (25.1%) | PreTax Margin | - | BV/Share | 128 | |||||
| 5Y Average FCF | ₹14B | 13.9% (1.6%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.00% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (13.9%) | ||||||||||
| 2027 | ₹19B | MBG Intrinsic Value | ₹85 | ||||||||
| 2028 | ₹21B | ||||||||||
| 2029 | ₹23B | ||||||||||
| 2030 | ₹25B | ||||||||||
| 2031 | ₹26B | ||||||||||
| 2032 | ₹27B | ||||||||||
| Terminal Value | ₹605B | Net Worth/Share | ₹128 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹514B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹14B | ₹890 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹5B | WACC | 6.5% | 836 | 909 | 1,000 | 1,118 | 1,273 | |||
| Equity Value | ₹524B | 7.1% | 744 | 800 | 867 | 951 | 1,058 | ||||
| Shares Outstanding | 588,403,502 | 7.8% | 669 | 713 | 764 | 826 | 903 | ||||
| 8.4% | 608 | 643 | 683 | 730 | 788 | ||||||
| DCF Intrinsic Value | ₹890 | 9.0% | 558 | 586 | 618 | 656 | 700 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||